Thrilled to share that Rosario Fernandez Godino, Head of Screening and Target Validation at @medinadiscovery.bsky.social, has presented m3DinAI at #BIO2025!
@biotechnology-bio.bsky.social #BIOInternational #Biotech #IA #Cancer #3Dtumor_spheroid_models #HTS @universidadgranada.bsky.social
@biotechnology-bio.bsky.social #BIOInternational #Biotech #IA #Cancer #3Dtumor_spheroid_models #HTS @universidadgranada.bsky.social
June 18, 2025 at 9:44 AM
Thrilled to share that Rosario Fernandez Godino, Head of Screening and Target Validation at @medinadiscovery.bsky.social, has presented m3DinAI at #BIO2025!
@biotechnology-bio.bsky.social #BIOInternational #Biotech #IA #Cancer #3Dtumor_spheroid_models #HTS @universidadgranada.bsky.social
@biotechnology-bio.bsky.social #BIOInternational #Biotech #IA #Cancer #3Dtumor_spheroid_models #HTS @universidadgranada.bsky.social
🚀 @medinadiscovery.bsky.social is heading to #SLAS2026 in #Vienna!
Our Head of Screening and Target Validation, Rosario Fernández Godino, will be presenting m3DinAI, our newest imaging platform for the screening of antitumoral drugs.
📍 Thursday, May 21, 2026 · 11:30 CEST
Our Head of Screening and Target Validation, Rosario Fernández Godino, will be presenting m3DinAI, our newest imaging platform for the screening of antitumoral drugs.
📍 Thursday, May 21, 2026 · 11:30 CEST
May 13, 2026 at 8:24 AM
🚀 @medinadiscovery.bsky.social is heading to #SLAS2026 in #Vienna!
Our Head of Screening and Target Validation, Rosario Fernández Godino, will be presenting m3DinAI, our newest imaging platform for the screening of antitumoral drugs.
📍 Thursday, May 21, 2026 · 11:30 CEST
Our Head of Screening and Target Validation, Rosario Fernández Godino, will be presenting m3DinAI, our newest imaging platform for the screening of antitumoral drugs.
📍 Thursday, May 21, 2026 · 11:30 CEST
Our Head of Screening and Target Validation, Rosario Fernández-Godino, presented m3DinAI Drug Quest, a pipeline developed by MEDINA to accelerate cancer drug discovery.
A big thank you to the SLAS community for such a stimulating event. See you next year! 👋
A big thank you to the SLAS community for such a stimulating event. See you next year! 👋
May 22, 2026 at 9:14 AM
Our Head of Screening and Target Validation, Rosario Fernández-Godino, presented m3DinAI Drug Quest, a pipeline developed by MEDINA to accelerate cancer drug discovery.
A big thank you to the SLAS community for such a stimulating event. See you next year! 👋
A big thank you to the SLAS community for such a stimulating event. See you next year! 👋
@medinadiscovery.bsky.social #DrugDiscovery #HighThroughputScreening #DrugDiscovery #ScreeningTechnologies @universidadgranada.bsky.social
MSD España Junta de Andalucía #MEDINA15_Years #3DCellCulture #m3DinAI
MSD España Junta de Andalucía #MEDINA15_Years #3DCellCulture #m3DinAI
November 21, 2025 at 8:41 AM
@medinadiscovery.bsky.social will be partnering at #BIO2025, June 16-19 in Boston and will showcase m3DinAI, our advanced AI-powered algorithm that harnesses 3D spheroid models to revolutionize cancer drug discovery.
May 14, 2025 at 7:24 AM
@medinadiscovery.bsky.social will be partnering at #BIO2025, June 16-19 in Boston and will showcase m3DinAI, our advanced AI-powered algorithm that harnesses 3D spheroid models to revolutionize cancer drug discovery.
Ayer, Inmaculada Iáñez, Bioinformática Junior en Fundación MEDINA, debutó como ponente en el III Congreso de Investigación del PTS Granada, presentando m3DinAI. Este innovador proyecto demuestra cómo la inteligencia artificial está marcando un antes y un después en la investigación científica.
February 5, 2025 at 3:02 PM
Ayer, Inmaculada Iáñez, Bioinformática Junior en Fundación MEDINA, debutó como ponente en el III Congreso de Investigación del PTS Granada, presentando m3DinAI. Este innovador proyecto demuestra cómo la inteligencia artificial está marcando un antes y un después en la investigación científica.